| 000 | 04753naa a22006497i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-PS-023 | ||
| 003 | local | ||
| 005 | 20261005174850.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2022 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1136/bmjgh-2022-008477 _2doi |
|
| 035 | _a(local)OpenAlex:W4281556556 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aAndrew T Levin _eauthor. |
|
| 245 | 1 | 0 |
_aAssessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications / _cAndrew T Levin; Nana Owusu-Boaitey; Sierra Pugh [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bBMJ, _c2022. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aThe source lists 18 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest. | ||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aINTRODUCTION: The infection fatality rate (IFR) of COVID-19 has been carefully measured and analysed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. METHODS: We systematically reviewed the literature to identify all COVID-19 serology studies in developing countries that were conducted using representative samples collected by February 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analysed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible. RESULTS: In most locations in developing countries, seroprevalence among older adults was similar to that of younger age cohorts, underscoring the limited capacity that these nations have to protect older age groups.Age-specific IFRs were roughly 2 times higher than in high-income countries. The median value of the population IFR was about 0.5%, similar to that of high-income countries, because disparities in healthcare access were roughly offset by differences in population age structure. CONCLUSION: The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to ensure medical equity to populations in developing countries through provision of vaccine doses and effective medications. | |
| 540 |
_aCreative Commons Attribution-NonCommercial (licence family recorded by the source; version not supplied in metadata). _uhttps://openalex.org/W4281556556 |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from OpenAlex bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Political Science. | ||
| 650 | 4 | _aCOVID-19 pandemic | |
| 650 | 4 | _ainfection fatality rate | |
| 650 | 4 | _aseroprevalence | |
| 650 | 4 | _adeveloping countries | |
| 650 | 4 | _aseroreversion | |
| 650 | 4 | _aantibody assays | |
| 653 | _aB. Sc. Political Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _apublic policy | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aNana Owusu-Boaitey _eauthor. |
|
| 700 | 0 |
_aSierra Pugh _eauthor. |
|
| 700 | 0 |
_aBailey K Fosdick _eauthor. |
|
| 700 | 0 |
_aAnthony B Zwi _eauthor. |
|
| 700 | 0 |
_aAnup Malani _eauthor. |
|
| 700 | 0 |
_aSatej Soman _eauthor. |
|
| 700 | 0 |
_aLonni Besançon _eauthor. |
|
| 700 | 0 |
_aIlya Kashnitsky _eauthor. |
|
| 700 | 0 |
_aSachin Ganesh _eauthor. |
|
| 700 | 0 |
_aAloysius McLaughlin _eauthor. |
|
| 700 | 0 |
_aGayeong Song _eauthor. |
|
| 773 | 0 |
_tBMJ Global Health _gVol. 7, no. 5, (2022), pages/article e008477 _x2059-7908 |
|
| 856 | 4 | 0 |
_uhttps://gh.bmj.com/content/bmjgh/7/5/e008477.full.pdf _yRead open-access publication _zOpen access. Access and licence reported by the source; this host could not be independently checked by automation. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from OpenAlex metadata. _g20261005 _khttps://openalex.org/W4281556556 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c970 _d970 |
||